CRTX — CRISM Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £4.40m
- £2.53m
Annual cashflow statement for CRISM Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Changes in Working Capital | — | — | — | — | 0.294 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.49 | -1.71 | -1.33 | -2.73 | -2.23 |
| Capital Expenditures | -0.393 | -0.44 | -0.31 | -0.265 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.001 | -3.6 | 4.7 | 0.114 | 28.1 |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.392 | -4.04 | 4.39 | -0.151 | 28.1 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.18 | 7.72 | 0 | 0.28 | -25.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.673 | 1.87 | 2.83 | -2.6 | 0.611 |